Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SANCUSO
- Bioequivalence Study in Healthy Chinese Subjects Comparing SP-01 (Granisetron Patch) Manufactured at Two Different Sites
- Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
- Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
- Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
- Treatment Algorithm for Nausea and Vomiting in the Palliative Phase
- Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting
- Sancuso® for Gastroparesis: An Open Label Study.
- Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)
- Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)
- Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
- Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
- Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
- Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
- Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
- Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
- Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)
- PK, Tolerability and Safety of the co-Administration of Sancuso® (Transdermal Granisetron) and IV Granisetron
- An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron
- R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Clinical trials list
click for details